375 related articles for article (PubMed ID: 31668406)
1. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
[TBL] [Abstract][Full Text] [Related]
2. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
6. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
8. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
10. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
[TBL] [Abstract][Full Text] [Related]
11. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
12. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
14. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
15. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
16. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
19. Deepening the Knowledge of
Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
[No Abstract] [Full Text] [Related]
20. Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Bubendorf L; Büttner R; Al-Dayel F; Dietel M; Elmberger G; Kerr K; López-Ríos F; Marchetti A; Öz B; Pauwels P; Penault-Llorca F; Rossi G; Ryška A; Thunnissen E
Virchows Arch; 2016 Nov; 469(5):489-503. PubMed ID: 27535289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
